The International Society for the Application of Stem Cells presents the schedule of International Cellular therapy certifications for 2024.

Miami, Florida – ISSCA, the International Society for Stem Cell Application and the Educational Division of Global Stem Cells Group, a global leader in cellular therapies and regenerative medicine education, proudly unveils its 2024 schedule for upcoming training dates in multiple countries. In alignment with ISSCA’s mission to extend the benefits of regenerative medicine to all, the organization invites the participation of physicians interested in advancing their expertise in the field.

ISSCA’s commitment to advancing regenerative medicine is exemplified by providing participants with exclusive access to the latest cutting-edge technologies in biologics and regenerative medicine products.

Participants are expected to learn valuable insights into the practical applications of these technologies and acquire knowledge on how regenerative medicine can contribute to addressing contemporary medical challenges, ultimately enhancing patient care.

ISSCA’s comprehensive training program comprises a one-day theoretical segment in which participants learn the fundamentals of cell therapies. It includes discussions on relevant cases and technologies. The practical part encourages participants to apply these therapies on real patients, a portion that lasts from one to two days depending on the ISSCA educational program in the country of the training. Technologies covered include exosomes, umbilical cord stem cells (where permitted), bone marrow and fat stem cells, PRP, and various alternative therapies.

These certifications are meticulously designed for physicians and specialists seeking to expand their knowledge of regenerative medicine and integrate diverse cell therapies into their medical practices.

Key Training Dates for 2024:

• Cancun, Mexico: February 9, 10, and 11
• Istanbul, Turkey: February 23 and 24
• Buenos Aires, Argentina: March 8 & 9
• Cancun, Mexico: March 22, 23, and 24
• Brussels, Belgium: March 29 and 30
• Cancun, Mexico: April 5, 6, and 7
• Lisbon, Portugal: April 12 and 13
• Fort Lauderdale, USA: April 19 and 20
• Santo Domingo, Dominican Republic: May 3 & 4
• Dubai, UAE: May 17-18
• Istanbul, Turkey: May 24-25
• Cancun, Mexico: June 14, 15, and 16
• Buenos Aires, Argentina: June 28-29
• Istanbul, Turkey: July 5 and 6
• Cancun, Mexico: August 9-10-11

For more information on ISSCA certifications and to make reservations, visit https://www.issca.us/, email info@stemcellsgroup.com, or call +1305 560 5337.

About ISSCA:

ISSCA is the educational division of Global Stem Cells Group, serving as a multidisciplinary community of scientists and physicians aspiring to treat disease and diminish human suffering through advances in the science, technology, and practice of regenerative medicine. ISSCA serves its members through advances made in the specialty of regenerative medicine.

ISSCA offers certification training in cities around the world, recognizing the importance of standards and certifications in regenerative medicine as a medical specialty. The mission is to promote quality and consistency in regenerative medicine worldwide.

About Global Stem Cells Group:

Global Stem Cell Group is a family of several companies focused on stem cell medicine and research. The company utilizes its network to provide leadership in regenerative medicine education, research, and patient applications.

GSCG’s mission is to enable physicians to present the benefits of stem cell medicine to patients worldwide. The company also collaborates with policymakers, educators, and regulators to promote regenerative medicine.

Global Stem Cells Group is a publicly traded company under the symbol MSSV. https://finance.yahoo.com/quote/mssv/.

For more information about Global Stem Cells Group, Inc. companies, visit our website www.stemcellsgroup.com or call +1 305 560 5331.

Safe Harbor Statement:

Statements in this news release may be “forward-looking statements.” Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Global Stem Cells Group (GSCG) and ReGen are thrilled to announce the grand opening of a new franchise clinic in Tashkent, Uzbekistan. The inauguration ceremony, attended by distinguished leaders in the field of regenerative medicine, marks a momentous occasion for healthcare in the region.

The event was graced by the presence of Dr. Salih Yildirim, Director of ReGen and President of the International Society for Stem Cell Application (ISSCA), and Benito Novas, the Director of Public Relations for both GSCG and ISSCA.

In addition to celebrating the clinic’s opening, the Tashkent center hosted the first ISSCA training program in the region, providing local physicians with the latest advancements in regenerative medicine.

Dr. Salih Yildirim expressed his delight, stating, “After inaugurating clinics in Istanbul (Turkey), Buenos Aires (Argentina), Cancun (Mexico), Miami (USA), and Jakarta (Indonesia), we are now here in Uzbekistan, in Tashkent. This moment fills me with great joy and a profound sense of purpose. It is a privilege to bring the benefits of regenerative medicine to the people of Uzbekistan”

Benito Novas added, “This is impressive. In the field of regenerative medicine, we aim to expand the movement, benefiting not only local patients but patients worldwide. This will undoubtedly be a great success. Regenerative medicine is not just the medicine of the future; it’s the medicine of the present.”

The newly established center will also serve as a training hub for ISSCA, contributing to the enhancement of knowledge and expertise among healthcare professionals in the region.

Partnership Between Global Stem Cells Group and ReGen

Through their strategic partnership, ReGen has experienced remarkable growth, leveraging Global Stem Cells Group’s reputation and extensive resources to open state-of-the-art clinics in several countries. These clinics have become pioneers in regenerative care in the region.

ReGen is at the forefront of introducing cutting-edge aesthetic treatments, such as the perfected hair transplant technique from Turkey, revolutionizing the regenerative healthcare landscape. Patients now have access to the latest and most effective treatment options. This partnership underscores Global Stem Cells Group’s vision to make its exceptional services accessible to people around the world.

While ReGen brings access to clinics, advanced techniques and expertise, Global Stem Cells Group provides valuable resources as a conglomerate of companies engaged in product manufacturing and comprehensive training through ISSCA. This collaboration has the potential to change the lives of people seeking regenerative care on a global scale.

This landmark partnership is poised to reshape the world of regenerative care, marking a transformative moment for the field of regenerative medicine.

For more information about Global Stem Cells Group and its regenerative medicine solutions, please visit https://www.stemcellsgroup.com/.

About Global Stem Cells Group

Global Stem Cells Group is a leading provider of regenerative medicine solutions, dedicated to advancing healthcare through innovative therapies. With a global presence and a multidisciplinary team of experts, the organization strives to harness the potential of stem cells and regenerative medicine to improve patient outcomes across various medical fields. Through its extensive network of clinics, research facilities, and training centers, Global Stem Cells Group is committed to pushing the boundaries of regenerative medicine and making a positive impact on global healthcare.

About ReGen

ReGen is a highly acclaimed Turkish company with clinics in Turkey and in several other locations around the world, renowned for its expertise in cutting-edge technologies related to regenerative care. Headquartered in Istanbul, ReGen has gained international recognition for its commitment to excellence and its groundbreaking advancements in regenerative medicine. By partnering with Global Stem Cells Group, ReGen aims to share its advanced techniques and expertise on a global scale, improving access to regenerative care and transforming lives worldwide.

Safe Harbor Statement: Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

For further information, please contact:

investor.relations@mssvinc.com

Telephone: (800) 956-3935

Miami, Florida – The International Society for Stem Cell Application (ISSCA) is pleased to announce a new date for practical certification at the highly anticipated 2023 World Congress of Regenerative Medicine in Istanbul, Turkey. Due to the overwhelming demand for clinical experience with real patients, ISSCA has extended the event, providing doctors with an extra day of hands-on training.

The original three-day event, scheduled from November 10 to 12, 2023, includes two days of stimulating conferences and lectures on November 10 and 11, conducted by distinguished physicians from around the world. This covers subjects pertinent to basic science, current advancements, and clinical experiences.

Due to an unprecedented response, the hands-on clinical experience day, November 12, is already at full capacity for the initial package subscribers. However, ISSCA has made the prudent decision to open a new date for training on November 13, 2023. This additional date offers an opportunity for new participants to benefit from valuable hands-on experience while also participating in the two days of conferences on November 10 and 11.

To facilitate a comprehensive understanding of the training and certification programs offered during the World Congress, ISSCA has launched a dedicated website showcasing agendas for various days and different package options. For more information, please visit https://www.issca.us/turkey-world-conference-2023/.

What to Expect at the ISSCA World Congress of Regenerative Medicine

The ISSCA World Congress of Regenerative Medicine serves as a global platform for the advancement of cellular therapies, related technologies, and clinical applications. This annual gathering brings together eminent scientists and physicians from over 30 countries for three days of conferences, lectures, and hands-on clinical application workshops.

Key focus areas for this year’s event include:

• Molecular Biology
• New treatment models in surgical and cosmetic applications
• The latest innovations in regenerative Medicine

Furthermore, the conference will explore the legal implications of regenerative medicine practices worldwide.

A Transformative Experience

The ISSCA 2023 World Congress in Istanbul is a must-attend event for all those interested in regenerative medicine. Focused on innovation, collaboration and knowledge sharing, the congress expects to be a transformative experience for scientists, physicians and healthcare professionals from around the world.

For more information about the November 10 to 13 ISSCA World Congress 2023, please visit our official website today.

About ISSCA:

The International Society for Stem Cell Application (ISSCA) is a multidisciplinary community of scientists and physicians who aspire to treat diseases and lessen human suffering through advances in science, technology, and the practice of regenerative medicine. ISSCA serves its members through advancements made in the specialty of regenerative medicine.

The mission of the International Stem Cell Certification Agency (ISSCA) is to establish itself as a global leader in regenerative medicine certification, education, research, and training.

ISSCA provides certification training in cities worldwide because it recognizes the importance of standards and certifications in regenerative medicine as a medical specialty. To help more people, both locally and globally, as the demand for more doctors interested in and comfortable with regenerative medicine surges. ISSCA’s mission is to advance quality and uniformity in regenerative medicine worldwide.

About Global Stem Cells Group:

The Global Stem Cell Group is a family of several companies focused on stem cell medicine and research. The company uses its network to bring leadership in regenerative medicine training, research, and patient applications.

GSCG’s mission is to allow physicians to present the benefits of stem cell medicine to patients worldwide. The company also partners with policymakers, educators, and regulators to promote regenerative medicine.

Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/

To learn more about Global Stem Cells Group, Inc.’s companies visit our website www.stemcellsgroup.com or call +1 305 560 5331

Safe Harbor Statement:

Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Miami, Florida – The International Society for Stem Cell Application (ISSCA) is delighted to announce its strategic partnership with the Turkish Stem Cell Society, along with the prestigious endorsement of three of Turkey’s top universities: Yeditepe University,  Atlas University and Marmara University. This collaboration marks a significant milestone in advancing the field of regenerative medicine and stem cell therapy in Turkey and beyond.

The annual Congress of Regenerative Medicine, scheduled to take place from November 10 to 12, 2023, will be hosted at the elegant Crowne Plaza Istanbul Florya Hotel in Istanbul, Turkey. This event is poised to serve as a pivotal platform for the exchange of groundbreaking advancements in stem cell therapy and regenerative medicine.

Partnership with Turkish Stem Cell Society and University Endorsements

The partnership with the Turkish Stem Cell Society underscores the commitment of ISSCA to advancing the field of regenerative medicine not only on a global scale but also within the vibrant Turkish scientific and medical community. Turkish Stem Cell Society has been at the forefront of research and innovation in stem cell therapy, making this collaboration a natural fit to foster greater knowledge sharing and cooperation.

Furthermore, ISSCA is honored to be endorsed by three of the most prestigious universities in Turkey:

Yeditepe University: Yeditepe University, a leading academic institution in Turkey, has a rich history of contributing to the fields of medicine and healthcare. Its endorsement of the Regenerative Medicine World Congress 2023 reaffirms the importance of this event in advancing the understanding of regenerative medicine.

Atlas University: Atlas University, with its commitment to research and innovation, plays a pivotal role in shaping the future of healthcare in Turkey. The university’s endorsement signifies the importance of regenerative medicine in modern medical practices.

Marmara University: Marmara University, recognized for its commitment to excellence in education, research, and innovation, is yet another prestigious institution supporting the congress. With a strong emphasis on interdisciplinary collaboration and cutting-edge research, Marmara University has become a center of intellectual discovery and academic achievement. The university’s renowned faculty and state-of-the-art infrastructure collaborate with Global Stem Cells Group to drive advances in regenerative medicine within the center, which is located on the university’s main campus.

World Congress Highlights

Representing over 35 countries, the Regenerative Medicine World Congress 2023 is set to be a hub of medical expertise. Renowned doctors and scientists from around the globe are expected to converge to share their insights and findings through evidence-based research presentations. This three-day symposium is designed to reshape medical understanding and ignite innovative possibilities.

A key feature of the congress is the immersive hands-on training, provided by ISSCA-certified instructors. Participants are expected to have the opportunity to delve into clinical and aesthetic applications of stem cell therapy over a single intensive day. This specialized training, guided by experts with extensive experience, equips attendees with practical skills that can be directly applied in their medical practice.

Collaboration and Appreciation

ISSCA is thrilled about the collaborative partnership with the Turkish Stem Cell Society and deeply appreciates the endorsements from Yeditepe University, Atlas University, and Marmara University. We look forward to the Regenerative Medicine World Congress 2023 as a significant step towards advancing the field of regenerative medicine. Your support and participation are invaluable, and we are genuinely excited to embark on this journey together.

For more information about the Regenerative Medicine World Congress 2023 and to register for this groundbreaking event, please visit www.issca.com

About the Turkish Stem Cell Society:

The Turkish Stem Cell Society is a leading organization dedicated to promoting ethical and responsible stem cell research and therapy in Turkey. They are committed to advancing scientific knowledge and education in the field of stem cells and regenerative medicine.

About ISSCA:

The International Society for Stem Cell Application (ISSCA) is a multidisciplinary community of scientists and physicians who aspire to treat diseases and lessen human suffering through advances in science, technology, and the practice of regenerative medicine. ISSCA serves its members through advancements made in the specialty of regenerative medicine.

The mission of ISSCA is to establish itself as a global leader in regenerative medicine certification, education, research, and training.

ISSCA provides certification training in cities worldwide because it recognizes the importance of standards and certifications in regenerative medicine as a medical specialty. To help more people, both locally and globally, as the demand for more doctors interested in and comfortable with regenerative medicine surges. ISSCA’s mission is to advance quality and uniformity in regenerative medicine worldwide.

About Global Stem Cells Group:

The Global Stem Cell Group is a family of several companies focused on stem cell medicine and research. The company uses its network to bring leadership in regenerative medicine training, research, and patient applications.

GSCG’s mission is to allow physicians to present the benefits of stem cell medicine to patients worldwide. The company also partners with policymakers, educators, and regulators to promote regenerative medicine.

Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/

To learn more about Global Stem Cells Group, Inc.’s companies visit our website www.stemcellsgroup.com or call +1 305 560 5331

Safe Harbor Statement:

Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

International Society for Stem Cell Application presents an unparalleled gathering of experts in Istanbul, Turkey.

Miami, Florida – The International Society for Stem Cell Application (ISSCA) is thrilled to unveil the remarkable roster of speakers for the highly anticipated Regenerative Medicine World Congress 2023. Set to take place from November 10 to 12, 2023, at the exquisite Crowne Plaza Istanbul Florya Hotel in Istanbul, Turkey, the congress is primed to be a convergence of minds dedicated to the advancement of stem cell therapy and regenerative medicine.

With over 35 countries represented, the Regenerative Medicine World Congress 2023 promises to be an extraordinary platform for knowledge exchange and scientific exploration. Distinguished doctors and scientists from across the globe will unite to discuss the latest developments in stem cell therapy and regenerative medicine through evidence-based research presentations.

Delegates attending the congress will have the unique opportunity to engage with more than 25 world-renowned medical experts who will present their insights and findings on a spectrum of issues related to this groundbreaking field. This three-day event is designed to foster interactive sessions, enabling attendees to deepen their understanding and broaden their perspectives on the applications of stem cell technology in various medical conditions.

Dr. Salih Yildirim, President of ISSCA, expressed his enthusiasm, saying, “I am delighted to witness the convergence of global medical experts in Istanbul. The Regenerative Medicine World Congress 2023 is an occasion to showcase our commitment to fostering international collaboration, sharing knowledge, and propelling medical progress.”

Echoing this sentiment, Benito Novas, an esteemed figure in the realm of regenerative medicine and the head of Public Relations for GSCG and ISSCA, highlighted ISSCA’s mission: “Our aim at ISSCA is to facilitate an environment of global collaboration and knowledge exchange. The Regenerative Medicine World Congress 2023 epitomizes this objective, offering a unique opportunity for professionals to engage in critical discussions, share insights, and collectively contribute to the advancement of medical science.”

A central highlight of the congress is the immersive hands-on training, facilitated by distinguished ISSCA-certified instructors. Participants will embark on an in-depth exploration of clinical and aesthetic applications of stem cell therapy during an intensive single-day workshop on November 12th. This comprehensive training, designed exclusively for those who secure the all-access package (limited to 20 seats), is guided by experts with extensive experience. Attendees are expected to acquire tangible skills that are readily applicable in their medical practice.

The congress will be inaugurated by Dr. Dayeong Kim from Korea and the President of ISSCA, Dr. Salih Yildirim. Their opening address will set the tone for an array of engaging sessions led by esteemed experts. Topics will span diverse medical conditions and real-world case studies, showcasing the application of stem cell therapy across various contexts.

Among the impressive lineup of speakers are luminaries such as:

– Dr. Dayeong Kim (Korea)

– Dr. Salih Yildirim (Turkey)

– Dr. Alan Gaveck (USA)

– Dr. Serdar Kabatas (Turkey)

– Dr. Yanti Kushmiran (Indonesia)

– Dr. Hilmi Karadeniz (Turkey)

– Dr. Roni Moya (Portugal)

– Dr. Tunç Akkoç (Turkey)

– Dr. Erdinc Civelek (Turkey)

– Dr. Mehmet Veli Karaaltın (Turkey)

– Dr. Ayman El Attar (USA)

– Prof. Utku Ates (Turkey)

– Dr. Fikrettin Şahin (Turkey)

– Dr. Emel Polat (Turkey)

– Dr. Patria Gonzalez (Dominican Republic)

– Dr. Ferda Alpaslan Pinarli (Turkey)

– Dra. Silvina Pastrana (Argentina)

– Dr. Samy Joheir (Belgium)

– Dr. Ahmet Doğan (Turkey)

– Dr. Jorge Elias (Argentina)

– Dr. Roland Neff (Switzerland)

– Prof. Aygen Türkmen (Turkey)

The Regenerative Medicine World Congress 2023 is an unparalleled opportunity for professionals to enrich their expertise, expand their network, and stay at the forefront of cutting-edge advancements in the field. To register and access detailed event information, please visit https://www.issca.us/turkey-world-conference-2023/ 

About ISSCA:

The International Society for Stem Cell Application (ISSCA) is a multidisciplinary community of scientists and physicians who aspire to treat diseases and lessen human suffering through advances in science, technology, and the practice of regenerative medicine. ISSCA serves its members through advancements made in the specialty of regenerative medicine.

The mission of the International Stem Cell Certification Agency (ISSCA) is to establish itself as a global leader in regenerative medicine certification, education, research, and training.

ISSCA provides certification training in cities worldwide because it recognizes the importance of standards and certifications in regenerative medicine as a medical specialty. To help more people, both locally and globally, as the demand for more doctors interested in and comfortable with regenerative medicine surges. ISSCA’s mission is to advance quality and uniformity in regenerative medicine worldwide.

About Global Stem Cells Group:

The Global Stem Cell Group is a family of several companies focused on stem cell medicine and research. The company uses its network to bring leadership in regenerative medicine training, research, and patient applications.

GSCG’s mission is to allow physicians to present the benefits of stem cell medicine to patients worldwide. The company also partners with policymakers, educators, and regulators to promote regenerative medicine.

Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/

To learn more about Global Stem Cells Group, Inc.’s companies visit our website www.stemcellsgroup.com or call +1 305 560 5331

Safe Harbor Statement:

Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Global Stem Cells Group (GSCG), a renowned leader in regenerative medicine, is thrilled to unveil its groundbreaking product, Cellgenic Lyophilized Exosomes – The Regen Series. We believe this product is set to revolutionize orthopedic and pain management applications, offering a remarkable potential for tissue regeneration in damaged areas of the body. Derived from human umbilical cord mesenchymal stem cells, Cellgenic Lyophilized Exosomes is a multifaceted solution that holds promise in addressing a wide range of ailments.

Cellgenic Lyophilized Exosomes contain a synergistic blend of essential components, including peptides, coenzymes, minerals, amino acids, vitamins, and UV radiation-reducing agents. These elements not only facilitate tissue regeneration but also make this product an exceptional option for skin revitalization. By utilizing this remarkable product, individuals may experience reduced pain levels.

A Revolutionary Product

Cellgenic Lyophilized Exosomes demonstrate unparalleled versatility and efficacy. Notably, this product requires no special storage conditions, enabling customers to utilize it conveniently at full capacity. Designed to combat inflammation and facilitate tissue repair, this targeted solution can significantly alleviate chronic pain, providing relief to those who have struggled to find effective solutions.

The exosome technology utilized in this product involves the freeze-drying of extracellular vesicles (EVs), which are kept separate from the mesenchymal stem cell cultures expanded in the laboratory. The Lyophilized Exosomes are then reconstituted with saline in front of the patient, just before use. This approach has proven to be highly effective in reducing inflammation and managing pain.

Global Stem Cells Group Remains a Leader in the Industry

One of the things that has helped set Global Stem Cells Group apart from the competition is their willingness to think in innovative ways that others simply do not. For example, the brand-new Lyophilized Exosome product can be shipped anywhere around the world without refrigeration. This allows for the possibility of getting it out to the places that truly need it without the burdensome ordeal of having to maintain the medication at a certain temperature. This is a problem for many medications, but GSCG has made sure that its products are more versatile than that.

Growing Faster Than Ever Before

Global Stem Cells Group has a lot going for it as far as its growth trajectory is concerned. They already have multiple offices around the globe, and they are always looking to expand their outreach by opening offices wherever it is prudent to do so. We believe the new product, Lyophilized Exosomes – The Regen Series, is set to strengthen GSCG’s position as a global leader in the regenerative and restorative medicine space for now and long into the future.

Benito Novas, CEO of Global Stem Cells Group, expressed his excitement about the company’s growth and stated, “Our goal at Global Stem Cells Group is to develop the most effective regenerative products on the market. Our new product line of lyophilized exosomes is a testament to our commitment to developing cutting-edge products with great clinical utility.”

About Global Stem Cells Group

Global Stem Cells Group (GSCG) is a world-renowned leader in regenerative medicine, specializing in innovative solutions that harness the power of stem cells for therapeutic applications. With a global network of offices and an unwavering commitment to excellence, GSCG continues to shape the future of regenerative and restorative medicine through groundbreaking products and advanced treatment protocols.

Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/

Safe Harbor Statement: Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.